Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of $0.27, $0.45 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $29.6 million versus the consensus estimate of $28.11 million.

GUIDANCE:

Anika Therapeutics sees FY2026 revenue of $114-122.5 million, versus the consensus of $117.2 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.